Cigna Group Executive Neville Everett Sells 617 Shares for $175,000

Neville Everett, Executive Vice President and Special Advisor to the CEO at The Cigna Group (NYSE:CI), sold 617 shares of common stock on Sept. 3, 2026, according to a SEC Form 4 filing.

Transaction summary

Metric	Value
Shares sold	617
Transaction value	~$175,259
Post-transaction shares (directly held)	5,053
Post-transaction value	$1.45 million

Transaction value based on SEC Form 4 weighted average sale price ($284.05); post-transaction value based on Sept. 3, 2026, market close ($286.26).

Key questions

• How did the pre-arranged trading plan influence the timing of this sale?
  The disposition was executed under a Rule 10b5-1 trading plan adopted on June 2, 2026, a mechanism that establishes a predetermined schedule for equity sales and removes discretionary timing from the process.
• What is the current scale of the executive's direct equity interest in the company?
  Following the disposal of 617 shares, the insider maintains a direct position of 5,053 shares, which carries a market value of $1.45 million based on the Sept. 3, 2026, market close price of $286.26.
• How does this equity sale relate to the company's performance over the past year?
  The executive sold shares at $284.05 per share on a date when the company's stock had generated a one-year total return of -2.7% as of the Sept. 3, 2026 market close.
• What is the executive's total ownership stake in the firm following this transaction?
  The executive currently holds 0.0019% of the common stock in Cigna Group, with all reported equity held directly according to the filing.

Company Overview

Metric	Value
Share Price (as of market close 2026-09-08)	$275.83
Market Capitalization	$72.5 billion
Revenue (TTM)	$282.5 billion
Net Income (TTM)	$6.9 billion

Company Snapshot

• The Cigna Group operates through two primary segments: Evernorth, which provides coordinated and specialized health solutions including pharmacy services, benefits administration, care management and delivery, and advanced intelligence solutions; and its core insurance operations offering medical, dental, behavioral health, and supplemental insurance products across the United States.
• The company generates revenue through premium income from health insurance policies, pharmacy benefit management services, care coordination and management services, and benefits administration fees charged to employers, health plans, and government programs.
• Cigna serves a diverse clientele, including employers of all sizes, health plans, government programs, and individual consumers, positioning itself as a comprehensive healthcare solutions provider serving millions of members across medical, pharmacy, dental, and behavioral health services.

The Cigna Group is one of the largest integrated healthcare companies in the United States, with TTM revenues of $282.4 billion and a market capitalization of $73.1 billion, reflecting its substantial scale within the healthcare sector.

The company's competitive advantage derives from its integrated business model combining health insurance with pharmacy benefit management and care management services, enabling coordinated care delivery and operational efficiencies.

With approximately 66,685 employees and operations spanning medical insurance, pharmacy services, and specialized health solutions, Cigna is positioned as a diversified healthcare platform addressing multiple segments of the healthcare value chain.

What this transaction means for investors

This sale shouldn't concern investors. It was a small portion of the executive's total stake in the company's stock. Moreover, the sale was executed under a Rule 10b5-1 plan, which insiders commonly use to execute pre-planned sales for personal reasons unrelated to the company's fundamentals.

Importantly, Cigna continues to perform mostly in line with its historical trend. TTM revenue grew nearly 8% year over year, and operating margin held at 3.5%. This reflects tailwinds in the specialty pharmacy market, leading to greater affordability with generics and improved earnings growth.

The stock is trading off its 2024 highs and sitting at a modest forward price-to-earnings multiple of 8.7x. This is even as analysts project roughly 11% annualized earnings growth over the next several years.

John Ballard has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.